Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  NuPathe Inc    PATH

NuPathe Inc. is a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.Its primary product, Zecuity (sumatriptan iontophoretic transdermal) for the acute... 
03/28Earnings Release
More about the company
Latest news on NUPATHE INC
2014DJU.S. HOT STOCKS : Hot Stocks to Watch
2014 NUPATHE INC : Endo Merger Agreement with NuPathe Terminated
2014 NuPathe Terminates Agreement With Endo and Enters Into Agreement to Be Acquir..
2014 NUPATHE INC : NuPathe Inc. Stockholders Encouraged to Contact Securities Law Fir..
2013 NUPATHE INC : Program Participations and Positive Stock Movements - Research Rep..
2013 NUPATHE INC : NUPATHE INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investi..
2013 NUPATHE INC : INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of NU..
2013 NUPATHE INC : Harwood Feffer LLP Announces Investigation of NuPathe, Inc.
2013 NUPATHE INC : PATH SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter is Investi..
2013 NUPATHE INC : SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces In..
More news
Sector news : Pharmaceuticals - NEC
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
Richard S. Egosi President, Chief Executive Officer & Director
Deborah A. Griffin Chief Financial Officer, Treasurer, Director & VP
Mark W. Pierce Chief Scientific Officer & Vice President
Austin D. Kim Secretary
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results